一家名为Modulo Bio的初创公司近日宣布获得来自阿尔茨海默病药物发现基金会（ADDF）480万美元的战略投资，旨在推进对额颞叶痴呆（FTD）治疗的临床试验。这项颇具前景的研究旨在通过针对小胶质细胞的疗法，重塑大脑免疫系统至保护状态，从而对抗这一破坏性的疾病。

The FDA has approved Ono’s CSF1R inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumours (TGCT) that are not suitable for surgical resection. It will compete ...

More information: Jaroslaw Dulski et al, Global Presence and Penetrance of CSF1R -Related Disorder, Neurology Genetics (2024) ...